Lexicon Pharmaceuticals (LXRX) Operating Expenses (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Operating Expenses data on file, last reported at $22.1 million in Q1 2026.

• On a quarterly basis, Operating Expenses fell 17.98% year-over-year to $22.1 million in Q1 2026; TTM through Mar 2026 was $93.9 million, a 55.02% decrease from a year earlier, with the FY2025 full-year figure at $98.7 million, down 56.74% from the prior year.
• Operating Expenses for Q1 2026 stood at $22.1 million, up from $20.3 million in the prior quarter.
• Over the last five years, Operating Expenses for LXRX reached as high as $65.4 million in Q3 2024 and fell as low as $20.3 million in Q4 2025.
• Historically, Operating Expenses has averaged $36.6 million across 5 years, with a median of $30.3 million in 2022.
• Across the five-year window, Operating Expenses soared 115.24% in 2023 and slumped 65.81% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $30.3 million in 2022, then soared by 56.53% to $47.4 million in 2023, then rose by 24.98% to $59.3 million in 2024, then slumped by 65.81% to $20.3 million in 2025, then increased by 9.0% to $22.1 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $22.1 million in Q1 2026, $20.3 million in Q4 2025, and $26.4 million in Q3 2025.